Thermo Cardiosystems Heartmate LVAS device exempt from tracking requirements, FDA says.
This article was originally published in The Gray Sheet
Executive Summary
THERMO CARDIOSYSTEMS DEVICE TRACKING EXEMPTION FOR HEARTMATE LVAS is granted by FDA in a Sept. 20 response to the company's July 1994 variance petition for its implantable pneumatic left ventricular assist system. In granting the exemption, FDA agrees with TCI's argument that the HeartMate's currently approved use as a temporary implantable device in hospital settings does not meet the agency's criteria for mandatory device tracking.
You may also be interested in...
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.